JEPRIFA-550
Description_Effects
JEPrifa-550 contains Rifaximin 550 mg, a broad-spectrum, gut-targeted antibiotic used to treat traveler’s diarrhea caused by the bacteria Escherichia coli (E. coli). This condition is common in individuals visiting regions with lower hygiene or food safety standards and is characterized by loose stools, abdominal cramps, bloating, and urgency. Rifaximin works by inhibiting bacterial RNA synthesis, preventing the growth and multiplication of bacteria directly within the intestines. Because it is minimally absorbed into the bloodstream, JEPrifa-550 acts locally in the gut, making it highly effective for intestinal infections with minimal risk of systemic side effects. JEPrifa-550 is especially indicated for non-invasive traveler’s diarrhea—cases where there is no fever or blood in the stool. It provides rapid relief from symptoms, often within the first 24 to 48 hours, and is typically taken for a 3-day course or as directed by a physician. In addition to treating traveler’s diarrhea, Rifaximin 550 mg is also commonly prescribed for other gastrointestinal conditions such as hepatic encephalopathy and irritable bowel syndrome with diarrhea (IBS-D), under medical supervision. JEPrifa-550 should be taken exactly as prescribed to ensure complete bacterial eradication and to reduce the risk of antibiotic resistance.
